Focus: Sentia Medical Sciences is a San Diego-based biotechnology company specializing in novel peptide therapeutics. The company currently operates a portfolio of radiopharmaceutical diagnostics post-loss of exclusivity.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Sentia Medical Sciences to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Sentia Medical Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
ANDA-approved radiopharmaceutical diagnostic now past loss of exclusivity with limited commercial value.
Help build intelligence for Sentia Medical Sciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ANDA-approved radiopharmaceutical diagnostic now past loss of exclusivity with limited commercial value.
ANDA-approved radiopharmaceutical diagnostic now past loss of exclusivity with limited commercial value.
ANDA-approved radiopharmaceutical now past loss of exclusivity.
ANDA-approved radiopharmaceutical diagnostic now past loss of exclusivity with limited commercial value.
ANDA-approved radiopharmaceutical diagnostic now past loss of exclusivity with limited commercial value.
ANDA-approved radiopharmaceutical diagnostic now past loss of exclusivity with limited commercial value.
ANDA-approved radiopharmaceutical diagnostic now past loss of exclusivity with limited commercial value.
ANDA-approved radiopharmaceutical diagnostic now past loss of exclusivity with limited commercial value.
ANDA-approved radiopharmaceutical diagnostic now past loss of exclusivity with limited commercial value.
6 discontinued, 8 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub